FINERENONE - AN OVERVIEW

There have been no clinically considerable distinctions within the pharmacokinetics of possibly midazolam (CYP3A4 substrate) or repaglinide (CYP2C8 substrate) when made use of concomitantly with finerenone. A number of doses of 40 mg finerenone the moment-daily experienced no clinically pertinent impact on AUC or Cmax of your BCRP and OATP substrat